It is the first once-daily oral Complement Factor B inhibitor ever approved, anywhere in the world. A second Chinese application, on the same molecule, covering PNH patients who have failed prior C5 ...

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of ...

A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, ...

Nuvectis Pharma (NASDAQ: NVCT) announced this morning that ciprocopan (NXP100) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with ...